II. Regulatory Landscape and Global Market Integration
NMPA
The NMPA classifies punctal plugs as Class III medical devices under the code 16-07-05, denoting the highest level of regulatory scrutiny. Specialized applicators used for insertion are categorized as auxiliary devices.
Key products such as the PVP-based plugs and PLGA-based biodegradable plugs have already been approved and commercialized. The regulatory emphasis lies in demonstrating the primary mechanism as mechanical rather than pharmacological—particularly for HA-based gels. Domestic manufacturers have presented comprehensive equivalency assessments comparing their innovations with existing products in terms of intended use and mechanism, asserting that differences in material composition do not compromise safety or efficacy.
FDA
In the United States, punctal occlusion devices are cleared under the 510(k) process and categorized as “Intracanalicular Plugs” (Product Code LZU). Though unclassified by the FDA’s formal device classification system, they are subject to rigorous biocompatibility and clinical validation.
PVP-Based Products
The “Form Fit® Hydrogel Canalicular Plug” by Oasis Medical is a hallmark FDA-cleared PVP device. It has undergone extensive testing and received multiple 510(k) clearances based on structural conformity, safety, and clinical effectiveness.
HA-Based Injectable Gels
The first injectable HA canalicular gel product, developed by Visant Medical, gained clearance by demonstrating substantial equivalence to the aforementioned PVP product. Despite differences in delivery (prefilled syringe vs. preloaded inserter) and material (crosslinked HA vs. PVP), the clinical outcome—effective mechanical blockage—was comparable. The product’s safety and efficacy were validated through multicenter randomized controlled trials.
PDO-Based Biodegradable Plugs
An emerging category is represented by PDO (polydioxanone) plugs from South Korean manufacturer Bio Optics. The product demonstrated equivalency to its predecessor through a comparative analysis of material properties, degradation time (90 vs. 180 days), sterility, and intended use.
III. Clinical Value and Key Benefits
The advent of advanced punctal occlusion therapies offers meaningful improvements over traditional DED management. Their clinical value is manifest in several aspects:
1. Targeted Tear Retention with Measurable Benefits
By directly addressing tear drainage dysfunction, these devices significantly increase tear meniscus height, extend tear break-up time (TBUT), and reduce hallmark symptoms such as dryness, burning, grittiness, and reflex tearing. Objective metrics such as Ocular Surface Disease Index (OSDI) scores also show marked improvement post-treatment.
2. Minimally Invasive and Reversible Intervention
Punctal occlusion procedures are typically performed in an outpatient setting under topical anesthesia, with minimal trauma. Removable options like PVP plugs and HA gels can be flushed out, while biodegradable variants (PLGA, PDO) eliminate themselves over time, reducing the need for additional interventions. This flexibility allows for iterative treatment planning and facilitates therapy evaluation.
3. Excellent Tolerability
Across multiple studies and post-market surveillance reports, the core materials—PVP, PLGA, HA, and PDO—demonstrate excellent safety profiles. Adverse events are generally mild and transient, including foreign body sensation, minor redness, and superficial keratitis. Serious complications such as dacryocystitis are exceedingly rare and typically resolve with conservative management.
4. Improved Patient Adherence
Unlike eye drops that require frequent administration, a single implantation of a plug or injection of gel can offer therapeutic benefits for months. This convenience greatly enhances adherence, particularly among elderly or physically limited patients.
5. Broader Application Scope
While primarily indicated for moderate to severe DED, punctal occlusion has other valuable uses:
- Augmenting the efficacy of topical agents like cyclosporine by prolonging ocular surface residence time.
- Mitigating post-surgical dry eye following LASIK or cataract surgery.
- Enhancing tolerance of contact lens wear.
- Serving as a diagnostic trial before considering permanent occlusion options.
IV. Challenges and Future Directions
Despite their promise, several challenges remain in optimizing the application of punctal plugs and gels.
1. Placement Precision and Retention Stability
Proper placement is critical for efficacy. Misalignment, displacement, or extrusion can compromise therapeutic outcomes. In injectable gel therapies, operator technique—specifically control over injection depth and volume—is paramount, necessitating thorough clinician training.
2. Personalized Material Selection
Each material type offers different properties: PVP is removable; PLGA degrades over months; HA gels last about six months; and PDO varies from 90 to 180 days. Matching these attributes to patient anatomy, disease severity, and treatment goals is essential for personalized care.
3. Long-Term Safety Monitoring
Although complications are rare, long-term use requires vigilance for issues like granuloma formation or infection. Standardized insertion protocols, sterile technique, and scheduled follow-ups are vital to minimizing risk.
4. Economic Considerations
These advanced therapies are generally more costly than conventional artificial tears or lubricating eye drops. Cost-benefit analyses and health economic studies are needed to justify broader adoption, especially in public health systems.
5. Regulatory Clarity on Drug-Device Combination Status
A nuanced regulatory challenge lies in categorizing products that may contain biologically active substances. It is critical to determine whether the primary mechanism is mechanical or pharmacologic, especially for HA-based or drug-loaded variants. Clarity in this domain will streamline approval pathways and guide innovation.
V. Outlook: Intelligent Occlusion and Next-Generation Therapies
As the field matures, the future of punctal occlusion therapy will likely be shaped by emerging technologies and materials:
- Smart Implants and Real-Time Monitoring: Development of devices capable of monitoring tear volume or releasing therapeutic agents in response to environmental triggers may revolutionize patient management.
- Multifunctional Biomaterials: Research is underway on hydrogels that combine mechanical occlusion with anti-inflammatory or epithelial repair properties, including HA gels embedded with therapeutic nanoparticles or cytokine modulators.
- Enhanced Delivery Systems: Improvements in applicator ergonomics and gel rheology can ensure more consistent placement and optimize patient outcomes.
Punctal occlusion therapy, particularly with the advent of novel biomaterials like PVP, PLGA, and HA, has redefined how clinicians manage dry eye disease. These approaches address the condition’s root cause—tear deficiency—more effectively and conveniently than traditional therapies. While challenges remain in regulatory clarity, long-term safety, and cost efficiency, the rapid pace of innovation signals a future where dry eye patients can enjoy longer-lasting relief, greater treatment precision, and improved quality of life.